Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Glaukos Corp(GKOS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GKOS
11/06/2026: GKOS (3-star) is a STRONG-BUY. BUY for 10 days. Simulated Profits (25.88%). Updated daily EoD!
Glaukos Corp is a specialized medical technology company that has built a leading position in the micro-invasive glaucoma surgery (MIGS) market. The company’s primary strength lies in its ability to combine proprietary surgical hardware with sustained-release drug delivery platforms, such as the newly launched iDose TR. This diversification represents a significant growth opportunity as the firm aims to transition patients from topical treatments to recurring procedural care. However, the company faces notable execution risks, including intense competition from global medical device incumbents and the need for sustained, high-level investment in R&D. Glaukos may best suit growth-oriented investors who can tolerate volatility while monitoring progress on new product adoption and clinical pipeline milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company's expansion into new ophthalmic segments and drug delivery systems aligns with long-term capital appreciation goals. |
| Momentum investor | Mixed fit | Momentum participation depends heavily on positive clinical data and successful product rollout updates. |
| Value investor | Weak fit | The company trades at high valuation multiples typical of pre-profit/high-growth medical technology firms. |
| Dividend investor | Weak fit | Glaukos does not pay a dividend and reinvests all capital. |
| Low-risk investor | Weak fit | High volatility associated with clinical trial results and regulatory outcomes makes this unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock often reacts sharply to clinical trial updates and FDA regulatory decisions. |
| Valuation risk | Medium / high | Premium valuations leave little room for error if growth forecasts are missed. |
| Competition risk (Ophthalmic device incumbents) | Medium / high | Well-capitalized incumbents can exert pricing pressure or bundle competing products. |
| Business quality | Medium | While the platform is innovative, long-term profitability remains a developing part of the company's story. |
| Dividend income | Low / none | Investors should not expect income from this equity. |
| Execution risk | Medium / high | Successful commercial adoption of new products like iDose TR is critical for meeting growth targets. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 51.11% | Avg. Invested days 37 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.28B USD | Price to earnings Ratio - | 1Y Target Price 242.46 |
Price to earnings Ratio - | 1Y Target Price 242.46 | ||
Volume (30-day avg) 1.7M shares | Beta 0.68 | 52 Weeks Range 83.78 - 255.19 | Updated Date 11/08/2026 |
52 Weeks Range 83.78 - 255.19 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.95 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Glaucoma | iStent product family and surgical devices. | This is the primary revenue driver, leveraging specialized implants for glaucoma surgery. |
| Corneal Health | Photrexa and corneal cross-linking devices. | A growth segment focused on treating progressive corneal conditions. |
| Retina | Sustained-release drug delivery systems. | The emerging segment that represents the next phase of the company's drug platform. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-28 | When After Market | Estimate -0.12 | Actual 0.47 |
Profitability
Profit Margin -24.6% | Operating Margin (TTM) 0.39% |
Management Effectiveness
Return on Assets (TTM) -3.9% | Return on Equity (TTM) -22.84% |
Valuation
Trailing PE - | Forward PE 1666.67 | Enterprise Value 13.05B | Price to Sales(TTM) 19.24 |
Enterprise Value 13.05B | Price to Sales(TTM) 19.24 | ||
Enterprise Value to Revenue 18.9 | Enterprise Value to EBITDA -57.89 | Shares Outstanding 59.20M | Shares Floating 57.04M |
Shares Outstanding 59.20M | Shares Floating 57.04M | ||
Percent Insiders 3.6 | Percent Institutions 104.74 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.